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Genome-wide association studies (GWAS) in coronary artery disease (CAD) have identified 113 
66 loci at ‘genome-wide significance’ (p < 5 × 10-8) but a much larger number of putative loci 114 
at a false discovery rate (FDR) of 5%1-4. Here, we leverage an interim release of UK Biobank 115 
(UKBB) data to evaluate the validity of the FDR approach. We tested a CAD phenotype 116 
inclusive of angina (SOFT; Ncases=10,801) as well as a stricter definition without it (HARD; 117 
Ncases=6,482) and selected the former for conducting a meta-analysis with the two most 118 
recent CAD GWASs2-3. This approach identified 13 new loci at genome-wide significance, 12 119 
of which were in our previous 5% FDR list2, and provided strong support that the remaining 120 
FDR loci represent genuine signals. The set of 304 independent variants at 5% FDR in this 121 
study explain 21.2% of CAD heritability and identified 243 loci that implicate pathways in 122 
blood vessel morphogenesis as well as lipid metabolism, nitric oxide signaling and 123 
inflammation. 124 
 125 
 126 
Previous GWAS studies of CAD risk1-4 have interrogated a large number of cases and controls 127 
but remain less well-powered than GWAS of quantitative traits5. UKBB was established to 128 
improve understanding of the causes of common diseases including CAD, a leading health 129 
problem around the world6. In addition to self-reported disease outcomes and extensive 130 
health and life-style questionnaire data, the 502,713 participants are being tracked through 131 
their NHS records and national registries (including cause of death and Hospital Episode 132 
Statistics). In July 2015, UKBB released genotypes imputed to the 1000 Genomes panel for 133 
152,249 participants profiled with a SNP array harboring 820,967 variants comprising 134 
common variants optimized for imputation, validated rare coding variants and sets of 135 
phenotype-associated variants or their proxies (e.g. GWAS catalogue).   136 
We set up The UKBiobank-CardioMetabolic-Consortium CHD working group to assess the use 137 
of self-reported and hospital record data on CAD in UKBB and define the relevant case and 138 
control subgroups to undertake genetic analyses of CAD risk. 139 
The July 2015 release of UKBB comprises 10,801 genotyped individuals with an inclusive CAD 140 
phenotype (‘SOFT’) that incorporates self-reported angina or other evidence of chronic 141 
coronary heart disease, of which 6,482 have a more stringently defined CAD phenotype 142 
(‘HARD’) of myocardial infarction and/or revascularisation (Fig. 1a). After QC we analysed the 143 
SOFT and HARD cases separately against 137,914 controls for 9,149,595 variants present 144 
either in the CARDIoGRAMplusC4D 1000-Genomes GWAS2 or the MIGen/CARDIoGRAM 145 
Exome-chip study3-4. The SOFT definition was selected for the primary analysis based on 146 
power calculations (Supplementary Table 1). We found 4 (SOFT and HARD), 1 (SOFT only) and 147 
2 (HARD only) variants reaching genome-wide significance, all located in known CAD loci 148 
(Supplementary Figure 1).  149 
We then meta-analysed the UKBB data for each CAD definition with each of the two published 150 
data sets (Supplementary Figure 2) using an inverse-variance weighted fixed-effect (IVW-FE) 151 
model and double genomic control correction (Online Methods).  For both the SOFT and HARD 152 
definitions, we validated all 66 known CAD loci (72 independent variants with p < 1.2x10-3 153 
IVW-FE) with 43 and 37 respectively reaching genome-wide significance in this study 154 
(Supplementary Table 2). Outside the known CAD loci (1 Mb window centred on the 155 
published lead SNP) we found 9 new signals (in both SOFT and HARD) reaching genome-wide 156 
significance (Table 1 and Fig. 2). The anticipated increase in power with the SOFT definition 157 
(Supplementary Table 1) was attenuated by an inflation of the lambda statistic 158 
(Supplementary Table 3), potentially due to a combination of larger sample size (i.e. 159 
polygenicity) and a less homogeneous phenotype in the SOFT definition. Overall, there was 160 
strong concordance between corresponding signals for SOFT and HARD (Fig. 1b, 161 
Supplementary Table 4); subsequent analyses were undertaken using the SOFT meta-analysis 162 
results.  163 
To look for additional signals beyond the 9 that reached genome-wide significance (Fig. 2) we 164 
performed an FDR analysis and selected 23 suggestive signals at 1% FDR (p < 1.55x10-6 IVW-165 
FE; Supplementary Table 4) outside known CAD loci which we validated in an independent 166 
sample of up to 4,412 cases and 3,910 controls from the German MI-Family-Studies V and VI 167 
and a Greek case-control study (Supplementary Table 5). In total, we identified 13 new 168 
genome-wide significant CAD loci in the combined discovery and replication sample (Table 1, 169 
Supplementary Table 6).  170 
In our recent large-scale GWAS2, we reported 162, mainly common, variants at an FDR 171 
discovery cutoff of 5% showing conditional independent associations with the Pjoint test in 172 
GCTA7. Twelve of the 13 new sentinel SNPs were present or had a proxy (r2>0.8) among these 173 
162 variants2. Fig. 3 shows a strong linear relationship between association signals for these 174 
162 variants in the earlier2 and current analysis, with overall greater significance levels in the 175 
current meta-analysis. As expected, we observed an excess of small p-values for this set of 176 
variants in the UK Biobank alone (Supplementary Figure 3a). Monte Carlo simulations show 177 
that the expected number of replicated variants in the UK Biobank data is 56 (95% CI 42 – 69) 178 
(Supplementary Figure 3b) and we found 58 variants after allowing for multiple testing (q-179 
values < 0.05). This further confirms the validity of extended lists of associated variants based 180 
on FDR criteria. We therefore defined a new FDR list of association signals by performing an 181 
approximate joint association analysis with the GCTA software7 as described elsewhere2 using 182 
the 11,427 SNPs with 5%FDR. We identified 304 independent variants at Pjoint < 10-4, clustering 183 
in 243 putative CAD loci (Supplementary Table 7). The new 5%FDR set overlaps by 122 SNPs 184 
with the old set (75.3%; including proxies at an r2 > 0.8). We then assessed heritability using 185 
the independent set of 304 SNPs and obtained a heritability estimate of 21.2%.  The 186 
contribution to this heritability estimate of the 13 new loci (Table 1) was 1.03% whereas the 187 
new and known genome-wide significant CAD loci together explained 8.53% of CAD 188 
heritability. To further assess the validity and utility of the 5%FDR set, we tested the ability to 189 
predict CAD using genetic risk scores (GRS) based on either the 5%FDR SNPs (GRS1) or only 190 
CAD variants reaching genome-wide significance (GRS2; Online Methods) in an independent 191 
sample, EPIC-CVD8, comprising 7910 CHD cases and 12958 controls. In a model with age and 192 
sex, GRS1 increased the C-index by 0.25% compared to GRS2 (Supplementary Table 8). GRS1 193 
improved the point estimates of the HR compared to GRS2 mainly in the second (from 0.9116 194 
to 0.8314) and fourth quintile (from 1.0437 to 1.176), Supplementary Figure 4. 195 
We then explored the biology of the 13 new genome-wide significant CAD risk loci; 196 
Supplementary Figure 5 shows regional association plots. Supplementary Figure 6 provides 197 
in silico functional annotation (Online Methods) for each lead variant and its proxies (1000 198 
Genomes). We found compelling evidence to implicate candidate genes ITGB5, TGB1, PDE5A, 199 
ARHGEF26, FN1, CDH13, and HNF1 (detailed in Supplementary Note). The risk allele of 200 
rs150512726 (proxy for rs142695226; Table 1), causes a 3 amino acid deletion within the 201 
cytoplasmic tail of integrin subunit beta 5 (ITGB5), part of a heterodimer which regulates the 202 
activation of latent TGFB1 (Transforming growth factor beta 1)9-10. The intronic variant 203 
(rs8108632; Table 1) we identified in TGFB1, further implicates the TGFB1 pathway in CAD 204 
risk. TGFB1 is known to have important roles in endothelium and vascular smooth muscle11 205 
but has not been widely studied in atherosclerosis, though a recent study implicates TGF-β 206 
signalling downstream of CDKN2B in the CDKN2BAS cardiovascular risk locus12. eQTL analyses 207 
suggested candidate CAD risk genes (TDRKH, FN1, ARHGEF26, PDE5A, ARNTL, and CDH13) in 208 
six new loci (Supplementary Table 9). For example, the lead variant rs7678555 (Table 1) was 209 
found to be a strong eQTL (p=8.1x10-13 linear regression model) for PDE5A only in aorta from 210 
CAD patients (STARNET13; Supplementary Table 9) although its regulatory potential was 211 
modest using functional prediction tools (Online methods). PDE5A encodes a cGMP-specific 212 
phosphodiesterase which is important for smooth muscle relaxation in the cardiovascular 213 
system where it regulates nitric-oxide-generated cGMP14. Furthermore, mining eQTL data in 214 
tissues from CAD patients (STARNET) showed several other instances of eSNPs (TDRKH, FN1, 215 
CDH13; Supplementary Table 9) having no effect in tissues from non-CAD patients (GTEx15). 216 
One caveat is that sample size differs between STARNET and GTex for certain tissues. 217 
Nonetheless, our observation highlights the need to expand efforts to map regulatory 218 
elements in disease tissues.  219 
Other candidate genes fit with emerging data on atherosclerosis mechanisms. For example, a 220 
knockout mouse for ARHGEF26 on a hyperlipidemic background resulted in reduced 221 
atherosclerosis and plaques with reduced macrophage content16. Similarly, FN1 expression is 222 
increased in plaques and mouse models have demonstrated a causal role for fibronectin-1 in 223 
the development and progression of atherosclerosis17-18. Finally, we undertook a phenome 224 
scan to assess pleiotropy (Supplementary Table 10). Several of the new lead SNPs (or a proxy) 225 
had robust associations (p < 5x10-8 meta-analysis) with traditional CAD risk factors such as 226 
LDL-cholesterol (HNF1A and FN1), blood pressure (PRDM8/FGF5) and BMI (SNRPD2).  227 
 228 
We next evaluated the broader functional relationships among genes associated with variants 229 
(N=11,427) at 5%FDR. The 5%FDR set was annotated for eQTLs which, when present, were 230 
mainly found in atherosclerotic aortic wall (25%) or internal mammary artery (22%) of CAD 231 
patients (STARNET13; Supplementary Table 9). In GTEx15, eQTLs were mainly found in 232 
subcutaneous fat (Supplementary Table 9; Supplementary Figure 7). 233 
Prior pathway analyses of GWAS CAD loci have highlighted genes involved in lipid metabolism, 234 
cellular movement, and processes such as tissue morphology and immune cell trafficking1. 235 
Analysis of 357 genes, selected as either eQTLs and/or the nearest gene to a 5%FDR 236 
independent variant in this study (N=304), with the Ingenuity Knowledge base confirmed the 237 
above findings1 highlighting cardiovascular system development and function (p = 1.31x10-16 238 
right-tailed Fisher Exact Test (rtFET)), organismal development (p = 1.31 x 10-16 rtFET) and survival 239 
(p = 1.52x10-16 rtFET) as the most significant processes. In addition to canonical pathways 240 
related to lipid metabolism, extracellular matrix, inflammation and nitric oxide production, 241 
the 357 gene set showed enrichment for angiogenesis and signalling by the pro-angiogenic 242 
growth factor VEGF (Supplementary Figure 8). We also applied DEPICT19 with the full 243 
distribution of 5%FDR signals (Online Methods) to search for enriched gene sets. Blood vessel 244 
development, which includes angiogenesis, was in the top 10 (p < 6.67x10-12 enrichment 245 
test19) DEPICT Grouped-GeneSets (GO:0001568; Fig. 4, Supplementary Figure 9, 246 
Supplementary Table 11). 247 
Ingenuity built 5 networks out of the 357 genes with the largest three integrating 12 of the 248 
new candidate CAD risk genes with 67 candidate genes in known CAD loci (Supplementary 249 
Table 12). In total, the 5 networks comprise 66.4% of the 357 genes. 250 
This is the largest CAD genetic study to assess simultaneously common and rare (MAF < 251 
1%)/low-frequency (MAF 1-5%) variants. In total, 101 low-frequency and 3 rare variants 252 
reached genome-wide significance among all 5%FDR markers (N=11,427). This apparent 253 
paucity in rare variants which has also been reported for type 2 diabetes20, is likely due to lack 254 
of power compared to studies of quantitative traits e.g. a study of adult height in ~700,000 255 
individuals has reported 32 rare variants5. As expected, lower-frequency variants tend to have 256 
stronger effects compared to common variants (Supplementary Figure 10) with the exception 257 
of rs2891168 in CDK2NB-AS1 (MAF 48.7%; OR 1.19; Supplementary Table 13). The intergenic 258 
variant rs186696265 which had the largest OR (1.62) in our study is known to affect LDL 259 
cholesterol levels21.  260 
Our findings highlight the importance of the FDR approach to define an extended list of 261 
associated variants. As we have previously proposed1-2, suggestive association signals in well-262 
powered GWAS such as this one can substantially improve our knowledge of disease 263 
architecture at only a modest penalty implied by the 5%FDR. We have demonstrated the 264 
potential value of the new 5%FDR list in improving prediction of CAD risk and implicating new 265 
networks underlying CAD pathophysiology. This extended list of candidate genes provides a 266 
powerful resource for functional studies. 267 
We note that while this work was in review a study was published also reporting 268 
associations of the HNF1A locus with CAD22. 269 
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  410 
Figure legends 411 
Figure 1. Description of HARD and SOFT CAD phenotypes in UK Biobank. (a) Diagram depicting 412 
the CAD phenotype definition in UK Biobank. HARD CAD defined as fatal or non-fatal 413 
myocardial infarction (MI), PTCA (percutaneous transluminal coronary angioplasty), or 414 
coronary artery bypass grafting (CABG). SOFT CAD includes HARD CAD as well as chronic 415 
ischaemic heart disease (IHD) and angina. UK Biobank self-reported data: ‘Vascular/heart 416 
problems diagnosed by doctor’ or ‘Non-cancer illnesses that self-reported as angina or heart 417 
attack’. Self-reported surgery defined as either PTCA, CABG or triple heart bypass. HESIN 418 
hospital episodes data and death registry data using diagnosis and operation - primary and 419 
secondary cause: MI defined as hospital admission or cause of death due to ICD9 410-412, 420 
ICD10 I21-I24, I25.2; PTCA is defined as hospital admission for PTCA (OPCS-4  K49, K50.1, K75); 421 
CABG is defined as hospital admission for CABG (OPCS-4 K40 – K46); Angina or chronic IHD 422 
defined as hospital admission or death due to ICD9 413, 414.0, 414.8, 414.9, ICD10 I20, I25.1, 423 
I25.5-I25.9. (b) Radar plot highlighting the proportions (%) of signals between the HARD and 424 
SOFT CAD phenotype definitions based on the 5%FDR results (Supplementary Table 4); MAF 425 
= minor allele frequency, p < 5x10-8 marks variants reaching genome-wide significance, OR = 426 
odds ratio (OR > 1.05 corresponds to 85% power to detect a signal (alpha < 0.05) in the SOFT 427 
analysis). The results for all six subgroups of variants assessed did not differ statistically 428 
between the two phenotype definitions (p>0.1) 429 
Figure 2. Transposed Manhattan plot showing the SOFT meta-analysis results under an 430 
additive model. The P-values are truncated at –log10(P) = 20. Markers shown are from the 431 
meta-analysis of UK Biobank with the 1000G GWAS data2 unless flagged by an * (exome chip 432 
markers). The red dotted lines are at GWAS (P=5x10-8) and 5% FDR significance (P=6.28x10-5). 433 
The known CAD risk loci are shown in black (Supplementary Table 2); KSR2 and ZNF507-434 
LOC400684 had reached genome-wide significance under a recessive model2. The 435 
11p15_MRVI1 / CTR9 locus had discordant results between the CAD 1000 Genomes GWAS2 436 
and Exome4 data set. The lead variant in the Exome data set, rs11042937, had P = 3.21 x 10-437 
8; data shown are from the meta-analysis with the 1000Genomes GWAS as this marker had 438 
an imputation info score of 1 (Online Methods). The 13 novel CAD loci which reached genome-439 
wide significance in our study (including replication data; Table 1), are written in brown font. 440 
Figure 3. Single marker p-value comparison of the 5% FDR variants in the published 441 
CARDIoGRAMplusC4D 1000Genomes CAD GWAS meta-analysis2 and current FDR study. Of 442 
the 162 variants which had p <5x10-5 in the CAD 1000Genomes GWAS, 116 had a match or 443 
good proxy (r2 > 0.8) in the new FDR list (blue circles). SNPs in red (n=7) were present in the 444 
earlier FDR list and reached genome-wide significance in the current analysis. 445 
Figure 4. Heat map showing the DEPICT gene set enrichment results with zoom-in on a subset 446 
of the results. 556 gene sets are included which had evidence of enrichment at 1% FDR. The 447 
x– axis shows the gene name, which is predicted to be included in the reconstituted gene set 448 
indicated in the y – axis.  The color red indicates higher Z-score, where Z-score is a value 449 
representing each gene’s inclusion in DEPICT’s reconstituted gene sets. Clustering was made 450 
based on complete linkage method. Highlighted pathways in the cluster, include 451 
angiogenesis, blood vessel development and morphogenesis. 452 
 453 
  454 
Table 1-Novel variants reaching genome-wide significance (P<5x10-8) in the combined (discovery and replication) SOFT meta-analysis  455 
 456 
Locus Name Markername CHR POS (hg38) EA EAF 
Functional 
Evidence 
UKBB+CoG/Exome Meta analysis 
OR 95% CI Pvalue FDR Qvalue OR 95% CI Pvalue 
TDRKH rs11810571 1 151762308 G 0.849 eQTL/coding 1.060 1.039-1.082 2.21x10-8 8.05x10-5 1.057 1.036-1.079 4.24x10-8 
FN1 rs1250229* 2 216304384 T 0.256 eQTL/coding 1.072 1.052-1.092 1.85x10-13 2.05x10-9 1.071 1.051-1.091 2.77x10-13 
RHOA rs7623687 3 49448566 A 0.855 none 1.074 1.049-1.100 3.72x10-9 1.62x10-5 1.076 1.052-1.101 3.44x10-10 
UMPS/ITGB5 rs142695226 3 124475201 G 0.138 eQTL/coding 1.069 1.045-1.094 1.00x10-8 3.98x10-5 1.071 1.048-1.095 1.53x10-9 
ARHGEF26 rs12493885* 3 153839866 C 0.886 eQTL 1.074 1.047-1.101 3.29x10-8 1.15x10-4 1.073 1.047-1.101 3.16x10-8 
PRDM8/FGF5 rs10857147 4 81181072 T 0.275 none 1.056 1.036-1.075 8.96x10-9 3.60x10-5 1.054 1.036-1.073 5.66x10-9 
PDE5A/MAD2L1 rs7678555 4 120909501 C 0.301 eQTL 1.049 1.031-1.069 1.43x10-7 4.25x10-4 1.052 1.034-1.070 1.32x10-8 
HDGFL1 rs6909752 6 22612629 A 0.351 none 1.051 1.034-1.069 5.59x10-9 2.35x10-5 1.051 1.034-1.068 2.19x10-9 
ARNTL rs3993105 11 13303071 T 0.704 none 1.048 1.030-1.067 1.06x10-7 3.33x10-4 1.048 1.031-1.066 4.77x10-8 
HNF1A rs2244608 12 121416988 G 0.355 coding 1.053 1.035-1.070 2.32x10-9 1.06x10-5 1.053 1.035-1.070 7.74x10-10 
CDH13 rs7500448 16 83045790 A 0.752 eQTL 1.061 1.040-1.082 5.14x10-9 2.18x10-5 1.063 1.043-1.083 4.76x10-10 
TGFB1 rs8108632 19 41854534 T 0.488 none 1.049 1.031-1.067 5.88x10-8 1.95x10-4 1.048 1.031-1.066 4.04x10-8 
SNRPD2 rs1964272 19 46190268 G 0.510 none 1.045 1.028-1.063 2.29x10-7 6.15x10-4 1.047 1.030-1.064 2.46x10-8 
*Exome marker 457 
EA: effect allele; EAF: Effect allele frequency; CoG = CARDIoGRAMplusC4D 1000G GWAS; Exome = Exome array analysis; UKBB = UK Biobank; 458 
Discovery sample comprised 71,602 cases and 260,875 controls (for exome markers 53,135 and 215,611 respectively); Replication sample 459 
comprised up to 4412 cases and 3910 controls. Functional evidence for the locus is given where the lead variant or a variant in high LD (r2>0.8) 460 
is a coding change, has evidence as an expression quantitative trait locus (eQTL), or both. Further details of functional evidence are provided in 461 
Supplementary Table 7 and Supplementary Figure 6. 462 
 463 
  464 
Online Methods 465 
Phenotype Definitions & Power calculation 466 
UKBB recruited 502,713 individuals aged 40-69 years from England, Scotland and Wales 467 
between 2006 and 2010 (94% of self-reported European ancestry). HARD CAD was defined 468 
as fatal or non-fatal myocardial infarction (MI), percutaneous transluminal coronary 469 
angioplasty (PTCA), or coronary artery bypass grafting (CABG). SOFT CAD includes all HARD 470 
CAD as well as chronic ischemic heart disease (IHD) and angina. Controls were defined as 471 
patients which were not a SOFT case after exclusions (listed below). All conditions were 472 
defined by either self-reported, hospital episode or death registry data. 473 
Exclusions were made for aneurysm and atherosclerotic cardiovascular disease using 474 
hospital admissions, or cause of death, codes ICD9 414.1, ICD 10 I25.0, I25.3, I25.4, and not 475 
having MI, PTCA, CABG, Angina or chronic IHD as defined above. 476 
Susceptibility effect sizes in MI cases and an inclusive CAD definition were very similar in 477 
the earlier GWAS2. We hypothesized that the detailed clinical information in UKBB might 478 
enhance the search for novel loci by further broadening the CAD phenotype to increase 479 
sample size. 480 
 481 
GWAS and meta-analyses  482 
All participants gave written consent for participation in genetic studies, and the protocol 483 
of each study was approved by the corresponding local research ethics committee or 484 
institutional review board. Participating cohorts in the 1000 Genomes and Exome GWAS 485 
studies are described elsewhere2,3. UK Biobank (UKBB samples) were excluded due to 486 
withdrawn consent, sex mismatches (n=182), Biobank/Believe QC exclusions (n=406) and 487 
sample relatedness (n=3,481) determined as Kinship>0.088. GWAS analysis in UKBB was 488 
restricted to variants with results available in the published GWAS2 or Exome3-4 dataset. 489 
Further exclusions included poorly imputed (info<0.4) or monomorphic variants, duplicate 490 
variants across data sets, variants that deviated strongly from Hardy-Weinberg Equilibrium 491 
in European ancestry controls (p<1x10-9), variants with an effect allele frequency in 492 
European ancestry samples that differed strongly (i) from 1000G European panel, (ii) from 493 
GWAS/Exome data, (iii) between arrays (UKBB vs UK-BiLEVE), and (iv) across genotyping 494 
batches. Variants that did not produce a valid result or estimated extreme log odds ratios 495 
(|beta|>4) were also excluded after analysis. Cluster plots lead variants and of proxies 496 
were visually inspected. 497 
We ran the GWAS under an additive frequentist mode of inheritance for each variant using 498 
the dosages from the imputed data, adjusting for array (UK Biobank vs UK BiLEVE) and the 499 
first five principal components (see URLs) using SNPTEST. Age and sex were not adjusted 500 
for to maximize the power to detect associations with diseases that have a prevalence 501 
<10%23. Population stratification was assessed and standard errors were adjusted using 502 
the genomic inflation statistic (λ). 503 
Association summary statistics (after λ correction) from the UKBB were combined with the 504 
1000 Genomes (1000G) imputed GWAS results2 and the Exome results3 via two separate 505 
fixed-effect inverse-variance weighted meta-analysis implemented in GWAMA24. We 506 
applied post meta-analysis λ correction in each instance. We identified 36,460 variants 507 
present in both the 1000G imputed GWAS and the Exome results. We retained the variants 508 
from the 1000G imputed GWAS if the median info score was 1, otherwise we retained the 509 
results from the Exome data. 510 
 511 
Comparison of SOFT vs HARD peak variant lists at 5% q-value  512 
The false discovery rate (FDR) following the meta-analysis with UKBB was assessed using a 513 
step-up procedure in the qqvalue Stata program25 as it is well controlled under positive 514 
regression-dependency conditions. We used the Simes method to generate q-values for 515 
the 8.9M variants. The p-value cut-off for a q-value of 5% for HARD was 7.24x10-5 and SOFT 516 
was 6.28x10-5. Peak SNPs were identified in a 1cM window. There is an exact overlap of 517 
155 variants between the 2 peak variant lists, however, using the 1cM window the overlap 518 
increases to 206 variants. Both the lists were annotated and classified into 6 categories 519 
(exome chip, indels, Odds Ratio (OR)>1.05, p<5e-8, MAF<5% and exonic). The proportions 520 
were calculated in each of the 6 categories and plotted as a radar plot (Fig. 1b). Monte 521 
Carlo simulations were used to assess the post-hoc power of the UKBB interim data to 522 
replicate the 155 variants. The 1000G GWAS effect sizes (“betas”) are expected to be 523 
subject to winner’s curse inflation so were shrunken (towards the null) by application of 524 
the FIQT procedure26. Effect sizes for firmly established CAD loci were systematically lower 525 
for SOFT compared to the HARD phenotype (Supplementary Table 1) noting that HARD 526 
closely corresponds to the CAD phenotype in reference 2. Betas were therefore further 527 
shrunken by a factor log (1.059)/log(1.072) = 0.82 (Supplementary Table 1). 10,000 528 
replicates were then randomly drawn from the vector of shrunken betas and the 529 
corresponding UKBB standard errors, to allow for variation in genotype call rates, 530 
imputation quality and allele frequency and to calculate Wald association statistics. 531 
Multiple testing of 155 variants was allowed for by controlling the FDR to 5% with a step-532 
up procedure encoded in the multproc27 Stata™ program. The average expected number 533 
of replicated variants was 56 (95%CI 42 – 69). Testing the 5% FDR variants (Supplementary 534 
Table 7) in UKBB with a model adjusted for age and sex gave concordant results to the 535 
unadjusted model (data not shown). 536 
  537 
GCTA & Heritability analysis  538 
We used the GCTA software7 to perform joint association analysis in (SOFT) meta-analysis 539 
results. This approach fits an approximate multiple regression model using summary-level 540 
meta-analysis statistics and LD corrections estimated from a reference panel (here the 541 
UKBB sample). We adopted a chromosome-wide stepwise selection procedure to select 542 
variants and estimate their joint effects at i) a genome-wide significance level (pJoint ≤ 543 
5x10-8) in the totality of meta-analysed variants (n~ 9M; Supplementary Figure 10, 544 
Supplementary Table 11) and ii) a Bonferroni-corrected pJoint<1x10-4 corresponding to 545 
the number of independent LD bins (r2 < 0.1) in the 5% FDR variant list (n=11,427; 546 
Supplementary Table 6). 547 
Heritability calculations were based on a multifactorial liability-threshold model, 548 
implemented in the INDI-V28 calculator (see URLs), under the assumption of a baseline 549 
population risk (K) of 0.071929 and a twins heritability (𝐻𝐿
2) of 0.4. Multiple regression 550 
estimates from the GCTA joint association analysis were used to estimate heritability for 551 
the 304 independent CAD risk variants within the 5% FDR list. 552 
 553 
Genetic risk score analysis  554 
GRS analysis was undertaken in the EPIC-CVD study8 which comprises 7910 CAD cases and 555 
12958 controls (Supplementary Note). We considered either all known and new lead CAD 556 
risk variants reaching genome-wide significance (GRS2; Supplementary Table 2 and Table 557 
1) or the 304 variants in the 5% FDR set (GRS1; Supplementary Table 7). We used variants 558 
with an INFO score filter of 0.4 in EPIC-CVD and replaced missing ones  with proxies (r2 > 559 
0.8 in 1000 Genomes European participants). GRS1 comprised 280 variants and GRS2 71. 560 
The raw GRS was obtained by summing the dosages of these variants for all individuals. 561 
We then fitted a Prentice weighted cox regression model for each GRS, adjusting for age 562 
and sex, to obtain survival forecasts and calculate the C indices. Statistical analyses were 563 
performed using R 3.3.3 and STATA 13.1. Variant extraction was done using qctool 1.4. 564 
 565 
Functional annotation 566 
eQTLs: For associations between the 304 independent variants (5% FDR) and gene 567 
expression traits we searched for expression quantitative trait loci (eQTLs) in the 568 
Stockholm-Tartu Atherosclerosis Reverse Network Engineering Task (STARNET) RNA-seq 569 
dataset13 and the Genotype-Tissue Expression15 (GTEx) portal. eQTLs were included if the 570 
best eSNP (i.e. the variant with the most significant association with gene expression in cis) 571 
was in high LD (r2>0.8) with the CAD lead SNP. 572 
Regulatory elements: We functionally annotated each of the 13 lead variants and their 573 
proxies (r2>0.8) using HaploregV430. Overlap with regulatory elements including 574 
chromosome state segmentation, DNase hypersensitivity, and transcription factor binding 575 
(TFB) as determined by the ENCODE31 and Roadmap Epigenome projects32, and predicted 576 
effects on TFB based on regulatory motifs from TRANSFAC33 and JASPAR34 were identified 577 
using HaploregV419 and the UCSC genome browser. Variants were then scored using three 578 
different bioinformatics tools that help prioritise causal disease variants. Combined 579 
Annotation Dependent Depletion (CADD)35 incorporates a range pathogenicity prediction 580 
tools to provide a genome-wide score (C-score) for each test variant from its pre-calculated 581 
database of ~8.6 billion genetic variants. High scores indicate variants that are not 582 
stabilized by selection and are more likely to be disease-causing and low scores indicate 583 
evolutionary stable non-damaging variants. The top 10% of likely functional variants will 584 
have a C-score >10 and top 1% of variants will have a C-score >20. Genome-wide 585 
annotation of variants (GWAVA)36 predicts the functional impact of noncoding variants 586 
based on genomic and epigenomic annotations and provides scores between 0 and 1 with 587 
higher scores indicating variants that are more likely to be functional. RegulomeDB37 588 
annotates and scores variants in seven categories based datasets such as ENCODE. Scores 589 
of 1-2 variants likely to affect TFB, 3 less likely to affect binding, 4-6 relate to variants with 590 
minimal binding evidence and 7 is for variants with no regulatory annotation. 591 
Phenome-scan: look ups in other common traits were performed using the PhenoScanner 592 
database as described in reference 38. 593 
 594 
Pathway analysis 595 
DEPICT: DEPICT19 is a computational tool which performs gene set enrichment analyses to 596 
prioritize genes in associated GWAS loci with probabilistically predefined gene sets based 597 
on Gene Ontology terms, canonical pathways, protein-protein interaction subnetworks 598 
and rodent phenotypes; reconstituted gene sets are detailed in references 19 and 39. Input 599 
to our analysis were the 11,427 CAD variants (FDR 5%) of which 11,311 were annotated in 600 
DEPICT. We constructed loci as previously described (beta version 1.1, release 194, see 601 
URLs). Analysis was performed with default parameters (50 repetitions to compute FDRs, 602 
500 permutations to adjust for biases, such as gene length). The 11,311 variants were 603 
collapsed to 288 loci which were used in the gene set enrichment analyses.  Correlated 604 
gene sets were grouped together based on gene membership to expedite data 605 
interpretation. 606 
Ingenuity: Genes were selected using 304 independent SNPs (5% FDR) based on eQTLs 607 
(Supplementary Table 9) and physical proximity (included overlapping genes on opposite 608 
strands or at equal distance from the SNP). Spliced ESTs and putative transcripts were not 609 
included. Network analysis was performed using the Ingenuity Pathway Analysis software 610 
(see URLs). We considered molecules and or relationships available in The IPA Knowledge 611 
Base (IKB) for human OR mouse OR rat and set the confidence filter to Experimentally 612 
Observed OR High (Predicted). Networks were generated with a maximum size of 70 genes 613 
and up to 10 networks were allowed. Networks are ranked according to their degree of 614 
relevance to the ‘eligible’ molecules in the query data set. The network score is based on 615 
the hypergeometric distribution and is calculated with the right-tailed Fisher's Exact Test. 616 
The significance p-value associated with enrichment of functional processes is calculated 617 
using the right-tailed Fisher Exact Test by considering the number of query molecules that 618 
participate in that function and the total number of molecules that are known to be 619 
associated with that function in the IKB. 620 
 621 
 622 
Data Availability Statement: Meta-analysis summary statistics for all variants considered 623 
in this study for association with CAD (SOFT definition) are available at 624 
http://www.cardiogramplusc4d.org/data-downloads/. 625 
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